C-PSJKBlue Rock Therapeutics (owned by Bayer)
cell therapy, cellular medicine
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-PSJK
C-PSJKC-PSJKcell therapy, cellular medicine
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Blue Rock Therapeutics (owned by Bayer) cell therapy, cellular medicine
BlueRock Therapeutics is a clinical-stage cell therapy company investigating medicines that replace cells damaged or lost to disease. Its programs include neurology and ophthalmology, with visible references to bemdaneprocel for Parkinson's disease and OpCT-001. The site describes its goal as transforming treatment of degenerative diseases through cellular medicine.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Blue Rock Therapeutics (owned by Bayer) — Near-term readout · Lower middle. Derived deterministically from 5 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic